AC Immune (ACIU) Enterprise Value (2016 - 2026)

AC Immune (ACIU) has reported Enterprise Value for 13 consecutive years, with -$95.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 58875.4% year-over-year to -$95.5 billion; the TTM figure through Mar 2026 stood at -$95.5 billion (down 58875.4% YoY), while the FY2025 annual figure was -$78.0 billion, down 41173.1% from the prior year.
• Enterprise Value slipped to -$95.5 billion in Q1 2026 per ACIU's latest filing, from -$80.9 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$90.5 million in Q3 2023 and bottomed at -$125.6 billion in Q1 2022.
• Historically, Enterprise Value has averaged -$23.4 billion across 5 years, with a median of -$162.0 million in 2025.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 99.91% — and 2026, when it slumped 58875.4%.
• AC Immune's Enterprise Value stood at -$127.2 million in 2022, then slipped by 28.41% to -$163.4 million in 2023, then decreased by 15.61% to -$188.9 million in 2024, then sank by 42714.39% to -$80.9 billion in 2025, then decreased by 18.1% to -$95.5 billion in 2026.
• Business Quant data shows ACIU's Enterprise Value at -$95.5 billion in Q1 2026, -$80.9 billion in Q4 2025, and -$135.6 million in Q3 2025.